These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27846274)

  • 1. Meta-Analysis and Advancement of Brucellosis Vaccinology.
    Carvalho TF; Haddad JP; Paixão TA; Santos RL
    PLoS One; 2016; 11(11):e0166582. PubMed ID: 27846274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.
    Todd TE; Tibi O; Lin Y; Sayers S; Bronner DN; Xiang Z; He Y
    BMC Bioinformatics; 2013; 14 Suppl 6(Suppl 6):S3. PubMed ID: 23735014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
    Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
    Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice.
    Kahl-McDonagh MM; Ficht TA
    Infect Immun; 2006 Jul; 74(7):4048-57. PubMed ID: 16790778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice.
    Surendran N; Sriranganathan N; Lawler H; Boyle SM; Hiltbold EM; Heid B; Zimmerman K; Witonsky SG
    Vaccine; 2011 Mar; 29(15):2749-55. PubMed ID: 21316499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipopolysaccharide as a target for brucellosis vaccine design.
    Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
    Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Brucella abortus membrane fusogenic protein induces protection against challenge infection in mice.
    de Souza Filho JA; de Paulo Martins V; Campos PC; Alves-Silva J; Santos NV; de Oliveira FS; Menezes GB; Azevedo V; Cravero SL; Oliveira SC
    Infect Immun; 2015 Apr; 83(4):1458-64. PubMed ID: 25644010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic and protective antigens of Brucella as vaccine candidates.
    Masjedian Jezi F; Razavi S; Mirnejad R; Zamani K
    Comp Immunol Microbiol Infect Dis; 2019 Aug; 65():29-36. PubMed ID: 31300122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6-10 months old water buffalo (Bubalus bubalis).
    Diptee MD; Adesiyun AA; Asgarali Z; Campbell M; Adone R
    Vet Immunol Immunopathol; 2006 Jan; 109(1-2):43-55. PubMed ID: 16112746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
    Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
    Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
    Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
    Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.
    Kahl-McDonagh MM; Arenas-Gamboa AM; Ficht TA
    Infect Immun; 2007 Oct; 75(10):4923-32. PubMed ID: 17664263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Efficacy of the Brucella canis RM6/66 Δ
    Stranahan LW; Chaki SP; Garcia-Gonzalez DG; Khalaf OH; Arenas-Gamboa AM
    mSphere; 2020 May; 5(3):. PubMed ID: 32434839
    [No Abstract]   [Full Text] [Related]  

  • 15. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of BALB/c mice with Brucella abortus 2308ΔwbkA confers protection against wild-type infection.
    Li ZQ; Gui D; Sun ZH; Zhang JB; Zhang WZ; Zhang H; Guo F; Chen CF
    J Vet Sci; 2015; 16(4):467-73. PubMed ID: 26040616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.
    Golshani M; Rafati S; Siadat SD; Nejati-Moheimani M; Shahcheraghi F; Arsang A; Bouzari S
    Mol Immunol; 2015 Aug; 66(2):384-91. PubMed ID: 25968974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and trial of vaccines against
    Lalsiamthara J; Lee JH
    J Vet Sci; 2017 Aug; 18(S1):281-290. PubMed ID: 28859268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of Brucella abortus rough vaccine strains to elicit DC and innate immunity in lung using a murine respiratory model.
    Surendran N; Zimmerman K; Seleem MN; Sriranganathan N; Boyle SM; Hiltbold EM; Lawler H; Heid B; Witonsky SG
    Vaccine; 2010 Oct; 28(43):7009-15. PubMed ID: 20727395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
    Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
    Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.